Enlight debuts new oral biologics delivery company, Entrega

Entrega, a new USA-based company developing oral drug delivery technologies, has been formed by Enlight Biosciences, a Boston-based firm established in partnership with a group of leading global pharmaceutical companies, including USA-based Abbott Labs, Johnson & Johnson, Eli Lilly, Merck & Co and Pfizer, as well as Switzerland’s Novartis.

As part of its initial development program, Entrega will use its unique spatially-directed proprietary drug delivery platform to create orally bioavailable formulations of several of the biologic drugs of Enlight's pharmaceutical industry partners, for which Entrega will receive undisclosed payments including upfront and research milestone payments. Entrega will remain independent and retain all rights to the platform technology.

"Entrega's technology could have a major impact on medicine by enabling the oral delivery of drugs that would typically require injection," said Robert Langer, David H Koch Institute Professor at MIT, chairman of Entrega’s scientific advisory board, noting that "the relationship with pharma will support Entrega's unique technology and strengthen the platform significantly."